US2015361080A1PendingUtilityA1
Substituted noribogaine
Est. expiryDec 20, 2032(~6.4 yrs left)· nominal 20-yr term from priority
A61K 31/55A61K 45/06C07D 471/22
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This invention relates noribogaine derivatives, compositions and methods of use thereof.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A compound Formula IA or Formula IB, or a pharmaceutically acceptable salt of each thereof:
wherein
R is OR 1 or C 1 -C 12 alkyl optionally substituted with 1 to 5 R 9 ;
R 1 is selected from the group consisting of hydrogen, —C(O)OX, —SO 2 OR 10 , a monophosphate, a diphosphate, a triphosphate, and —C(O)N(Y) 2 where X is C 1 -C 6 alkyl optionally substituted with 1 to 5 R 9 , and each Y is independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl optionally substituted with 1 to 5 R 9 , C 6 -C 14 aryl optionally substituted with 1 to 5 R 9 , C 3 -C 10 cycloalkyl optionally substituted with 1 to 5 R 9 , C 1 -C 10 heteroaryl having 1 to 4 heteroatoms and which is optionally substituted with 1 to 5 R 9 , C 1 -C 10 heterocyclic having 1 to 4 heteroatoms and which is optionally substituted with 1 to 5 R 9 , or where each Y, together with the nitrogen atom bound thereto form either a C 1 -C 6 heterocyclic having 1 to 4 heteroatoms and which is optionally substituted with 1 to 5 R 9 , or a C 1 -C 6 heteroaryl having 1 to 4 heteroatoms and which is optionally substituted with 1 to 5 R 9 ;
R′ is halo, OR 20 , or C 1 -C 12 alkyl optionally substituted with 1 to 5 R 9 ;
R 20 is selected from the group consisting of hydrogen, —C(O)X, —C(O)OX and —C(O)N(Y) 2 where X and Y are defined as above;
R 2 is hydrogen, —SO 2 OR 10 , a monophosphate, a diphosphate, or a triphosphate;
R 3 is selected from the group consisting of hydrogen, —(CH 2 ) m OR 7 , —CR 6 (OH)R 7 , —(CH 2 ) m CN, —(CH 2 ) m COR 7 , —(CH 2 ) m CO 2 R 7 , —(CH 2 ) m C(O)NR 6 R 7 , —(CH 2 ) m C(O)NR 6 NR 7 R 7 , —(CH 2 ) m C(O)NR 6 NR 7 C(O)R 8 , and —(CH 2 ) m NR 6 R 7 ;
m is 0, 1, or 2;
L is a bond or C 1 -C 12 alkylene;
R 4 is selected from the group consisting of C 1 -C 12 alkyl substituted with 1 to 5 R 9 , C 2 -C 12 alkenyl substituted with 1 to 5 R 9 , —X 2 —R 6 , —(X 2 —Y 2 ) n —X 2 —R 6 , —SO 2 NR 6 R 7 , —O—C(O)R 8 , —C(O)OR 7 , —C(O)NR 6 R 7 , —NR 6 R 7 , —NHC(O)R 8 , and —NR 6 C(O)R 8 ;
X 2 is selected from the group consisting of O and S;
Y 2 is C 1 -C 4 alkylene or C 6 -C 10 arylene, or a combination thereof;
n is 1, 2, or 3;
R 6 and R 7 are each independently selected from the group consisting of hydrogen, C 1 -C 12 alkyl optionally substituted with 1 to 5 R 9 , C 1 -C 6 heterocycle having 1 to 4 heteroatoms which is optionally substituted with 1 to 5 R 9 , C 3 -C 10 cycloalkyl optionally substituted with 1 to 5 R 9 , C 6 -C 10 aryl optionally substituted with 1 to 5 R 9 and C 1 -C 6 heteroaryl having 1 to 4 heteroatoms optionally substituted with 1 to 5 R 9 ; or
R 6 and R 7 are joined to form C 1 -C 6 heterocycle having 1 to 4 heteroatoms which is optionally substituted with 1 to 5 R 9 ;
R 8 is selected from the group consisting of C 1 -C 12 alkyl optionally substituted with 1 to 5 R 9 , C 1 -C 6 heterocycle having 1 to 4 heteroatoms optionally substituted with 1 to 5 R 9 , C 3 -C 10 cycloalkyl optionally substituted with 1 to 5 R 9 , C 6 -C 10 aryl optionally substituted with 1 to 5 R 9 and C 1 -C 6 heteroaryl having 1 to 4 heteroatoms optionally substituted with 1 to 5 R 9 ;
R 9 is selected from the group consisting of C 1 -C 4 alkyl, phenyl, halo, —OH, —OR 10 , —CN, —COR 10 , —CO 2 R 10 , —C(O)NHR 10 , —NR 10 R 10 , —C(O)NR 10 R 10 , —C(O)NHNHR 10 , —C(O)NR 10 NHR 10 , —C(O)NR 10 NR 10 R 10 , —C(O)NHNR 10 C(O)R 10 , —C(O)NHNHC(O)R 10 , —SO 2 NR 1 R 10 , —C(O)NR 10 NR 10 C(O)R 1 , —NHC(O)R 10 , C 1 -C 6 heterocycle having 1 to 4 heteroatoms optionally substituted with 1 to 5 R 10 , and —C(O)NR 10 NHC(O)R 10 ; and
R 10 is C 1 -C 12 alkyl;
provided that:
for the compound of Formula IA, when R is —OH or C 1 -C 12 alkyl optionally substituted with 1 to 5 R 9 , then R 3 is hydrogen; and
for the compound of Formula IA, when R 3 is hydrogen, and -L-R 4 is ethyl, then R is not
—OR 1 .
2 . A compound of Formula IIA or Formula IIB, or a pharmaceutically acceptable salt of each thereof:
wherein
R 11 is halo, —OH, —SH, —NH 2 , —S(O) 2 N(R 16 ) 2 , —X 1 -L 1 -R 17 , —X 1 -L 1 -R 1 , —X 1 -L 1 -R 19 , or —X 1 -L 1 -CHR 17 R 18 , where X 1 is O, S or NR 16 , or -O-Q, where Q is —SO 2 —(C 1 -C 12 alkyl), a monophosphate, a diphosphate, or a triphosphate;
L 1 is alkylene, arylene, —C(O)-alkylene, —C(O)-arylene, —C(O)O-arylene, —C(O)O— alkylene, —C(O)NR 19 -alkylene, —C(O)NR 19 -arylene, —C(NR 19 )NR 19 -alkylene or —C(NR 19 )NR 19 -arylene, wherein L 1 is configured such that -O-L 1 -R 17 is —OC(O)-alkylene-R 17 , —OC(O)O-arylene-R 17 , —OC(O)O-alkylene-R 17 , —OC(O)-arylene-R 17 , —OC(O)NR 19 -alkylene-R 17 , —OC(O)NR 19 -arylene-R 7 , -OC(NR 19 )NR 19 -alkylene-R 17 or —OC(NR 19 )NR 19 -arylene-R 7 , and wherein the alkylene and arylene are optionally substituted with 1 to 2 R 15 ;
R 12 is hydrogen, —S(O) 2 OR 19 , —S(O) 2 R 19 , —C(O)R 14 , —C(O)NR 14 R 14 , —C(O)OR 14 , C 1 -C 12 alkyl optionally substituted with 1 to 5 R 15 , C 1 -C 12 alkenyl optionally substituted with 1 to 5 R 15 , aryl optionally substituted with 1 to 5 R 15 , -SO 2 —(C 1 -C 12 alkyl), a monophosphate, a diphosphate, or a triphosphate;
R 13 is hydrogen, halo, —OR 16 , —CN, C 1 -C 12 alkyl, C 1 -C 12 alkoxy, aryl or aryloxy, where the alkyl, alkoxy, aryl, and aryloxy are optionally substituted with 1 to 5 R 15 ;
each R 14 is independently selected from the group consisting of hydrogen, C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, aryl, heteroaryl, and heterocycle, and wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocycle are optionally substituted with 1 to 5 R 15 ;
R 15 is selected from the group consisting of phenyl, halo, —OR 16 , —CN, —COR 16 , —CO 2 R 16 , —NR 16 R 16 ,—NR 16 C(O)R 16 ,—NR 16 SO 2 R 16 , —C(O)NR 16 R 16 , —C(O)NR 16 NR 16 R 16 , —SO 2 NR 16 R 16 and —C(O)NR 16 NR 16 C(O)R 16 ;
each R 16 is independently hydrogen or C 1 -C 12 alkyl optionally substituted with from 1 to 3 halo;
R 17 is hydrogen, —C(O)R 19 , —C(O)OR 19 , —C(O)N(R 19 ) 2 or —N(R 19 )C(O)R 19 ;
R 18 is hydrogen, —N(R 19 ) 2 , —C(O)N(R 19 ) 2 , —C(NR 19 )N(R 19 ) 2 , —C(NSO 2 R 19 )N(R 19 ) 2 , —NR 19 C(O)N(R 19 ) 2 , —NR 19 C(S)N(R 19 ) 2 , —NR 19 C(NR 19 )N(R 19 ) 2 , —NR 19 C(NSO 2 R 19 )N(R 19 ) 2 or tetrazole; and
each R 19 is independently selected from the group consisting of hydrogen, C 1 -C 12 alkyl and aryl;
provided that:
for the compound of Formula IIA:
when R 12 and R 13 are hydrogen, then R 11 is not hydroxy;
when R 13 is hydrogen, R is -O-L 1 -R 17 , -O-L 1 -R 18 , -O-L 1 -R 19 , and L 1 is alkylene, then -O-L 1 -R 17 , -O-L 1 -R 18 , -O-L 1 -R 19 are not methoxy; and
when R 13 is hydrogen, X 1 is O, L is —C(O)-alkylene, —C(O)-arylene, —C(O)O-arylene, —C(O)O-alkylene, —C(O)NR 19 -alkylene, or —C(O)NR 19 -arylene, then none of R 17 , R 18 or R 19 are hydrogen.
3 . The compound of claim 2 , represented by Formula IIC or Formula IID, or a pharmaceutically acceptable salt of each thereof:
4 . The compound of claim 2 , wherein R 11 is halo.
5 . The compound of claim 2 , wherein R 11 is bromo.
6 . The compound of claim 2 , wherein R 11 is —OH, -O-L 1 -R 17 , -O-L 1 -R 18 , -O-L 1 -R 19 or -O-L 1 -CHR 17 R 18 .
7 . The compound of claim 2 , wherein R 11 is —SH, -S-L 1 -R 17 , -S-L 1 -R 18 , -S-L 1 -R 19 or -S-L 1 -CHR 17 R 18 .
8 . The compound of claim 2 , wherein R 11 is —NH 2 , —NR 16 -L 1 -R 17 , —NR 16 -L 1 -R 18 , —NR 16 -L 1 -R 19 or —NR 16 -L 1 -CHR 17 R 18 .
9 . The compound of claim 2 , wherein R 11 is —S(O) 2 N(R 16 ) 2 .
10 . The compound of claim 2 , wherein R 1 is —Cl, —Br, —I, —OC(O)CH 2 CH 3 , -OC(O)CH 2 Ph, —OC(O)OCH 2 CH 3 , —OC(O)OCH 2 Ph, —OC(O)NH(CH(CH 3 )Ph), -OC(NPh)NHCH 2 CH 3 , —OC(O)NHCH 2 Ph, —NH 2 , —NHC(O)C(CH 3 ) 3 , —NHC(O)CF 3 , —NHC(O)CH 2 Ph, —NHC(O)OCH 2 Ph, —NHC(O)NH(CH(CH 3 )Ph), —SH, —SC(O)OCH 2 Ph, —SC(O)NH(CH(CH 3 )Ph), —SC(O)CH 2 CH 2 OP(O)(OH) 2 , —OC(O)CH 2 CH 2 CH(NH 2 )(CO 2 H), -O—(2-OH—C 6 H 3 )CH 2 CH(NH 2 )(CO 2 H) or —NHC(O)CH 2 CH 2 CH(NH 2 )(CO 2 H).
11 . The compound of claim 2 , wherein R 12 is hydrogen.
12 . The compound of claim 2 , wherein R 12 is —CH 2 CH 3 , —CH 2 CHCH 2 , —CH 2 Ph, —C(O)O(CH 2 ) 2 N(CH 3 ) 2 or —C(O)CH 2 (CH 2 ) 2 SO 2 N(CH 3 ) 2 .
13 . The compound of claim 2 , wherein R 13 is hydrogen.
14 . The compound of claim 2 , wherein R 13 is alkyl substituted with from 1 to 3 halo.
15 . The compound of claim 2 , wherein R 13 is trifluoromethyl.
16 . The compound of claim 2 , wherein R 13 is —OCH 3 , —OCH 2 CH 3 , —OCH 2 Ph or —CN.
17 . A compound of Formula IIE or a pharmaceutically acceptable salt thereof:
wherein the compound is selected form the group consisting of compounds wherein R 11 , R 12 , R 13 are defined as follows:
No.
R 11
R 12
R 13
1
Cl
H
H
double
bond
2
Br
H
H
double
bond
3
I
H
H
double
bond
4
—OC(O)CH 2 CH 3
H
H
double
bond
5
—OC(O)CH 2 Ph
H
H
double
bond
6
—OC(O)OCH 2 CH 3
H
H
double
bond
7
—OC(O)OCH 2 Ph
H
H
double
bond
8
—OC(O)NH(CH(CH 3 )Ph)
H
H
double
bond
9
—OC(NPh)NHCH 2 CH 3
H
H
double
bond
10
—OC(O)NHCH 2 Ph
H
H
double
bond
11
—NH 2
H
H
double
bond
12
—NHC(O)C(CH 3 ) 3
H
H
double
bond
13
—NHC(O)CF 3
H
H
double
bond
14
—NHC(O)CH 2 Ph
H
H
double
bond
15
—NHC(O)OCH 2 Ph
H
H
double
bond
16
—NHC(O)NH(CH(CH 3 )Ph)
H
H
double
bond
17
—SH
H
H
double
bond
18
—SC(O)OCH 2 Ph
H
H
double
bond
19
—SC(O)NH(CH(CH 3 )Ph)
H
H
double
bond
20
—SC(O)CH 2 CH 2 OP(O)(OH) 2
H
H
double
bond
21
—OC(O)CH 2 CH 2 CH(NH 2 )(CO 2 H)
H
H
double
bond
22
—O—(2-OH—C 6 H 3 )CH 2 CH(NH 2 )(CO 2 H)
H
H
double
bond
23
—NHC(O)CH 2 CH 2 CH(NH 2 )(CO 2 H)
H
H
double
bond
24
—OH
H
H
single
bond
25
Cl
H
H
single
bond
26
Br
H
H
single
bond
27
I
H
H
single
bond
28
—OC(O)CH 2 CH 3
H
H
single
bond
29
—OC(O)OCH 2 Ph
H
H
single
bond
30
—OC(O)NH(CH(CH 3 )Ph)
H
H
single
bond
31
—OC(O)NHCH 2 Ph
H
H
single
bond
32
—NH 2
H
H
single
bond
33
—NHC(O)C(CH 3 ) 3
H
H
single
bond
34
—NHC(O)NH(CH(CH 3 )Ph)
H
H
single
bond
35
—SH
H
H
single
bond
36
—SC(O)OCH 2 Ph
H
H
single
bond
37
—OH
—CH 2 CH 3
H
double
bond
38
—OH
—CH 2 CHCH 2
H
double
bond
39
—OH
—CH 2 Ph
H
double
bond
40
—OH
—C(O)O(CH 2 ) 2 N(CH 3 ) 2
H
double
bond
41
—OH
—C(O)CH 2 (CH 2 ) 2 SO 2 N(CH 3 ) 2
H
double
bond
42
—OH
H
—OCH 2 CH 3
double
bond
43
—OH
H
—OCH 2 Ph
double
bond
44
—OH
H
—CF 3
double
bond
45
—OH
H
—OH
double
bond
46
—OH
H
—CN
double
bond
18 . A compound of formula IC:
or a pharmaceutically acceptable salt thereof, wherein the compound is selected form the group consisting of compounds wherein R 10 is defined as follows:
TABLE 2
No.
R 10
47
NMe 2
48
OH
w49
NHC(O)Me
50
OMe
51
52
53
54
19 . A composition comprising a compound of claim 1 or 2 and a pharmaceutically acceptable excipient.
20 . A method of treating pain and/or addiction in a patient, comprising administering to said patient a compound of claim 1 or 2 or a pharmaceutically acceptable salt thereof or a composition of claim 19 .
21 . The method of claim 20 , which method is for treating neuropathic pain.
22 . The method of claim 20 , which method is for treating nociceptive pain.
23 . The method of claim 20 , which method alleviates a symptom associated with withdrawal from drug dependency selected from the group consisting of nausea, vomiting, anxiety, abdominal cramps, muscle pain, chills and headache.
24 . The method of claim 20 , wherein the addiction is an addicted to cocaine, alcohol, amphetamines or combinations thereof.
25 . The method of claim 20 , further comprising administering to the patient an opioid antagonist selected from the group consisting of naloxone, naltrexone and nalorphine.
26 . A method of treating nicotine addiction in a patient comprising administering to said patient an effective amount of a compound of claim 1 or 2 or a pharmaceutically acceptable salt thereof or a composition of claim 19 .
27 . A method of inhibiting a3b4 nicotinic acetylcholine receptors comprising administering an effective amount of a compound of claim 1 or 2 or a pharmaceutically acceptable salt thereof or a composition of claim 19 .Join the waitlist — get patent alerts
Track US2015361080A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.